转自：成都日报锦观 记者注意到，成都市银发经济重点产业链链主企业评定名单包括泰康之家蜀园（成都）健康服务有限公 司、成都九如城养老服务有限公司、四川千里倍益康医疗科技股份有限公司、都江堰五粮液合美健康投 资有限责任公司、四川科伦博泰生物医药股份有限公司、四川海思科制药有限公司、四川久远银海股份 有限公司、四川新绿色药业科技发展有限公司、成都第一制药有限公司9家企业。此外，银发经济重点 产业链链属企业共有412家，涵盖了健康养老、康养旅游、智慧养老、抗衰老产业、机器人等领域。 推动银发经济高质量发展，既是增进老年人福祉的现实需求，又是带动产业转型的时代机遇。《成都市 做优做强银发经济重点产业链三年行动计划》提出，到2027年，银发经济发展布局基本形成，优势特色 更加凸显，产业规模达1100亿元以上，争创一家国家级高水平银发经济产业园，打造15家以上具有全国 影响力的银发经济知名企业和一批品牌产品。 成都日报锦观新闻记者 刘泰山 9家企业入选成都市银发经济重点产业链链主 记者昨日从成都市发展改革委获悉，成都市银发经济重点产业链链主、链属企业评定结果正对外公示。 ...

Core Viewpoint - The clinical trial for HSK39297 tablets, aimed at treating primary IgA nephropathy, has been initiated, focusing on its efficacy and safety over a 48-week period [1][2]. Group 1: Clinical Trial Details - The trial is a multicenter, randomized, double-blind, placebo-controlled Phase III study with a registration number CTR20260278, first published on January 29, 2026 [1]. - The primary objective is to evaluate the effectiveness of HSK39297 in reducing proteinuria after 36 weeks and delaying the decline in renal function after 48 weeks in patients with primary IgA nephropathy [1]. - Secondary objectives include assessing the drug's effectiveness in delaying renal function decline and reducing proteinuria, as well as its impact on patients' quality of life and disease progression [1]. Group 2: Trial Endpoints - Primary endpoints include the ratio of 24-hour urine protein creatinine ratio (24h-UPCR) compared to baseline after 36 weeks and the annualized total slope of estimated glomerular filtration rate (eGFR) after 48 weeks [2]. - Secondary endpoints consist of various measures of eGFR and proteinuria at multiple time points (36, 48, and 104 weeks), as well as changes in plasma concentration of HSK39297 and adverse events during the study [2]. Group 3: Trial Status - The trial is currently ongoing and has not yet recruited participants, with a target enrollment of 370 individuals [3].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002653 证券简称：海思科 公告编号：2026-014 海思科医药集团股份有限公司 2026年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 4、召集人：海思科医药集团股份有限公司董事会 5、主持人：董事严庞科先生 重要内容提示： 本次股东会无增加、变更、否决提案的情况。 一、会议的召开和出席情况 1、现场会议召开时间：2026年1月28日14:00开始 2、现场会议召开地点：四川海思科制药有限公司办公楼三楼会议室。 3、会议召开方式：现场表决与网络投票相结合的方式。 其中通过深圳证券交易所交易系统进行网络投票的时间为2026年1月28日上午9:15一9:25，9:30一 11:30，下午13:00一15:00；通过互联网投票系统投票的时间为：2026年1月28日9:15至15:00期间的任意 时间。 6、本次股东会会议的召集、召开与表决程序符合《公司法》《公司股东会规则》《深圳证券交易所股 票上市规则》等法律、法规及规范性文件和《公司章程》的规定。 7、会议出席情况： ...

北京市中伦（深圳）律师事务所 关于海思科医药集团股份有限公司 2026 年第一次临时股东会的 法律意见书 二〇二六年一月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 北京市中伦（深圳）律师事务所 关于海思科医药集团股份有限公司 2026 年第一次临时股东会的 法律意见书 致：海思科医药集团股份有限公司 根据中国证监会发布的《上市公司股东会规则》（下称"《股东会规则》"） 的有关规定，北京市中伦（深圳）律师事务所（下称"本所"）接受海思科医药 集团股份有限公司（下称"公司"）的委托，指派律师出席公司 ...

证券代码：002653 证券简称：海思科 公告编号：2026-014 海思科医药集团股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 本次股东会无增加、变更、否决提案的情况。 一、会议的召开和出席情况 6、本次股东会会议的召集、召开与表决程序符合《公司法》《公 司股东会规则》《深圳证券交易所股票上市规则》等法律、法规及规 范性文件和《公司章程》的规定。 1 7、会议出席情况： （1）股东出席的总体情况： 通过现场和网络投票的股东 445 人，代表股份 322,779,482 股， 占公司有表决权股份总数的 28.8217％。其中通过现场投票的股东 3 人，代表股份 2,689,100 股，占公司有表决权股份总数的 0.2401％； 通过网络投票的股东 442 人，代表股份 320,090,382 股，占公司有表 决权股份总数的 28.5816％。 1、现场会议召开时间：2026 年 1 月 28 日 14:00 开始 2、现场会议召开地点：四川海思科制药有限公司办公楼三楼会 议室。 3、会议召开 ...

Investment Rating - The report maintains a positive investment rating for the pharmaceutical sector [5] Core Views - The report emphasizes three main investment themes for 2026: innovation, overseas expansion, and turnaround impulses, with a focus on BD2.0, small nucleic acids, and supply chain (CXO and upstream) [2][3] - The report suggests that the pharmaceutical sector is currently experiencing a rotation in investment focus, particularly in areas such as brain-computer interfaces, AI integration, small nucleic acids, and medical robotics [3] Summary by Sections Public Fund Holdings Update for Q4 2025 - Overall, the market value of public funds holding pharmaceutical stocks has decreased, with a total market value of 217.6 billion yuan, down by 51 billion yuan from the previous quarter [14] - The pharmaceutical sector's allocation in public funds is 7.96%, a decrease of 1.74 percentage points [19] - Chemical preparations remain the most heavily weighted sub-industry, while allocations to medical devices have increased [14][25] Market Review and Analysis - The pharmaceutical and biotechnology index decreased by 0.39% week-on-week, outperforming the CSI 300 index but underperforming the ChiNext index [1] - The total trading volume in the pharmaceutical sector was 554.24 billion yuan, accounting for 4.00% of the total trading volume in the Shanghai and Shenzhen markets [1] Investment Opportunities - The report identifies specific companies for potential investment, including: - CXO and innovative drug companies such as Tigermed, Zhaoyan New Drug, and Hai Si Ke, which have seen significant increases in fund holdings [16][38] - AI innovative drug companies like Jingtai Holdings and small nucleic acid firms such as Frontier Biotech and Yuyuan Pharmaceutical [3][38] - The report also highlights the importance of exploring CROs, essential drugs, and companies showing signs of bottoming out [3]

Core Viewpoint - The report highlights the performance of the China Europe Medical Health Mixed Fund managed by Ge Lan and Zhao Lei, indicating a decline in total fund size and negative returns compared to benchmarks [1][4]. Fund Performance - As of December 31, 2025, the total size of the funds managed by Ge Lan decreased from 43.544 billion to 35.389 billion yuan [1]. - The A-class share of the China Europe Medical Health Mixed Fund recorded a net value growth rate of -14.81%, while the C-class share saw a decline of -14.98%, both underperforming the benchmark return of -8.21% [1][3]. Holdings Overview - The top ten holdings of the China Europe Medical Health Fund include WuXi AppTec, Heng Rui Medicine, and Kanglong Chemical, with notable increases in holdings for Hai Si Ke and Tai Ge Medicine, while reductions were seen in stocks like Ke Lun Pharmaceutical and Xin Li Tai [1][2]. Market Context - In Q4 2025, the CSI Pharmaceutical Index fell by 12.7%, underperforming the CSI 300 Index, which declined by only 0.2%. The report notes significant differentiation within sub-sectors, with innovative industries experiencing corrections while traditional Chinese medicine and pharmaceutical commerce remained relatively stable [3]. Future Outlook - Looking ahead to Q1 2026, improvements in global liquidity are expected to boost investment and financing in innovative pharmaceuticals, supported by domestic policy enhancements. The innovative drug and device industry is anticipated to maintain a high level of activity, with several key domestic drugs approaching critical data readouts [4][5]. - The report suggests that the pharmaceutical sector may continue to experience structural trends due to macroeconomic improvements, supportive industry policies, and ongoing innovation, with investment opportunities focusing on the progress of innovative drug and device exports, domestic substitution in equipment, and recovery in consumer healthcare demand [5].

Core Viewpoint - The report highlights the performance of the China Europe Medical Health Mixed Fund, managed by Ge Lan and Zhao Lei, indicating a decline in total fund size and negative returns compared to benchmarks for the fourth quarter of 2025 [1][4]. Fund Performance - As of December 31, 2025, the total size of funds managed by Ge Lan decreased from 43.544 billion to 35.389 billion yuan [1]. - The net value growth rate for Class A shares of the China Europe Medical Health Mixed Fund was -14.81%, while the benchmark return was -8.21% [1]. - Class C shares experienced a net value growth rate of -14.98%, also underperforming the benchmark [1]. Holdings Overview - The top ten holdings of the China Europe Medical Health Mixed Fund include WuXi AppTec, Heng Rui Medicine, and Kanglong Chemical, with notable increases in holdings for Hai Si Ke and Tai Ge Medicine, while reductions were seen in stocks like Ke Lun Pharmaceutical and Xin Li Tai [1][2]. - The largest holding, WuXi AppTec, accounted for 10.11% of the fund's net value, with a market value of approximately 2.724 billion yuan [2]. Market Context - The CSI Medical Index fell by 12.7% in the fourth quarter of 2025, underperforming the Shanghai and Shenzhen 300 Index, which declined by only 0.2% [3]. - There was significant differentiation within sub-sectors, with the innovative industry chain entering a correction phase after previous gains, while traditional Chinese medicine and pharmaceutical commerce showed relative stability [3]. Future Outlook - Looking ahead to the first quarter of 2026, improvements in global liquidity are expected to boost investment and financing in innovative drugs, supported by domestic policy enhancements [4]. - The innovative drug and medical device industry chain is anticipated to maintain high levels of activity, with several key domestic drugs approaching critical data readout points [5]. - The CXO sector is expected to benefit from a recovery in biotechnology financing, leading to improved order conditions [5]. - The pharmaceutical sector is projected to experience structural trends driven by macroeconomic improvements, supportive industry policies, and ongoing innovation [5].

Group 1 - The A-share market saw a significant decline in innovative drug concept stocks, with notable drops including Aidi Pharmaceutical down over 11% and Yifang Bio down over 5% [1] - Other companies such as Xingqi Pharmaceutical, Zhenbaodao, and Dize Pharmaceutical experienced declines of over 4%, while Rongchang Bio, Hanshang Group, Yuekang Pharmaceutical, Xinlitai, Haishike, Shanghai Yizhong, and Kanghong Pharmaceutical fell by over 3% [1] Group 2 - Aidi Pharmaceutical (688488) reported a decline of 11.33%, with a total market value of 7.835 billion and a year-to-date increase of 14.02% [2] - Yifang Bio (688382) decreased by 5.99%, with a market capitalization of 15 billion and a year-to-date decline of 4.99% [2] - Xingqi Pharmaceutical (300573) fell by 4.82%, with a market value of 19.4 billion and a year-to-date increase of 12.01% [2] - Zhenbaodao (603567) dropped by 4.74%, with a market capitalization of 7.951 billion and a year-to-date decline of 5.38% [2] - Dize Pharmaceutical (688192) decreased by 4.19%, with a market value of 27.5 billion and a year-to-date increase of 2.78% [2] - Rongchang Bio (688331) fell by 3.98%, with a market capitalization of 56.1 billion and a year-to-date increase of 27.79% [2] - Hanshang Group (600774) decreased by 3.93%, with a market value of 3.101 billion and a year-to-date increase of 14.99% [2] - Yuekang Pharmaceutical (688658) dropped by 3.84%, with a market capitalization of 12 billion and a year-to-date increase of 18.40% [2] - Xinlitai (002294) fell by 3.32%, with a market value of 55.5 billion and a year-to-date increase of 0.48% [2] - Haishike (002653) decreased by 3.23%, with a market capitalization of 56.1 billion and a year-to-date decline of 2.44% [2] - Shanghai Yizhong (688091) dropped by 3.17%, with a market value of 11.2 billion and a year-to-date increase of 15.60% [2] - Kanghong Pharmaceutical (002773) fell by 3.15%, with a market capitalization of 29.5 billion and a year-to-date increase of 6.81% [2]

Core Viewpoint - The stock price of Haishike has experienced a decline, with a current trading price of 50.70 yuan per share, reflecting a year-to-date drop of 1.21% and a 5-day drop of 5.62% [1] Financial Performance - For the period from January to September 2025, Haishike achieved an operating revenue of 3.3 billion yuan, representing a year-on-year growth of 19.95%. However, the net profit attributable to shareholders decreased by 22.66% to 295 million yuan [2] - Cumulatively, Haishike has distributed a total of 3.673 billion yuan in dividends since its A-share listing, with 687 million yuan distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders of Haishike increased by 12.87% to 12,900, with an average of 37,342 circulating shares per person, down by 11.40% [2] - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3] Market Activity - As of January 22, Haishike's stock saw a trading volume of 51.53 million yuan, with a turnover rate of 0.21% and a total market capitalization of 56.78 billion yuan [1] - The main capital flow indicated a net outflow of 6.3653 million yuan, with significant selling activity observed [1]